Commodore Capital
Latest statistics and disclosures from Commodore Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are MRUS, NUVL, XENE, COGT, ELVN, and represent 37.18% of Commodore Capital's stock portfolio.
- Added to shares of these 10 stocks: COGT (+$71M), AMLX (+$55M), SLNO (+$50M), TERN (+$43M), ASMB (+$26M), Lb Pharmaceuticals (+$24M), ALKS (+$19M), RLAY (+$19M), PHVS (+$13M), PEPG (+$11M).
- Started 7 new stock positions in SABS, AMLX, PEPG, TERN, ASMB, ENTA, Lb Pharmaceuticals.
- Reduced shares in these 10 stocks: CDTX (-$57M), SRRK (-$51M), VRDN (-$36M), MNMD (-$21M), VERA (-$19M), XENE (-$13M), CLDX (-$11M), CNTA (-$11M), NGNE (-$6.4M), PTGX.
- Sold out of its positions in NGNE, SRRK, VERA.
- Commodore Capital was a net buyer of stock by $132M.
- Commodore Capital has $2.0B in assets under management (AUM), dropping by 44.59%.
- Central Index Key (CIK): 0001831942
Tip: Access up to 7 years of quarterly data
Positions held by Commodore Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Commodore Capital
Commodore Capital holds 37 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Merus N V (MRUS) | 16.2 | $332M | 3.5M | 94.15 |
|
|
| Nuvalent Inc-a (NUVL) | 5.9 | $121M | 1.4M | 86.48 |
|
|
| Xenon Pharmaceuticals (XENE) | 5.3 | $108M | -10% | 2.7M | 40.15 |
|
| Cogent Biosciences (COGT) | 5.1 | $104M | +213% | 7.3M | 14.36 |
|
| Enliven Therapeutics (ELVN) | 4.7 | $96M | 4.7M | 20.47 |
|
|
| Agios Pharmaceuticals (AGIO) | 4.6 | $94M | 2.3M | 40.14 |
|
|
| Alkermes SHS (ALKS) | 4.5 | $93M | +26% | 3.1M | 30.00 |
|
| Soleno Therapeutics (SLNO) | 4.5 | $91M | +121% | 1.4M | 67.60 |
|
| Relay Therapeutics (RLAY) | 4.3 | $89M | +27% | 17M | 5.22 |
|
| Celldex Therapeutics Com New (CLDX) | 3.8 | $78M | -12% | 3.0M | 25.87 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 3.4 | $69M | -13% | 2.9M | 24.25 |
|
| Miragen Therapeutics (VRDN) | 3.4 | $69M | -34% | 3.2M | 21.58 |
|
| Protagonist Therapeutics (PTGX) | 3.3 | $68M | -4% | 1.0M | 66.43 |
|
| Pharvaris N V (PHVS) | 2.9 | $60M | +26% | 2.4M | 24.95 |
|
| Cidara Therapeutics Com New (CDTX) | 2.7 | $56M | -50% | 585k | 95.76 |
|
| Amylyx Pharmaceuticals (AMLX) | 2.7 | $55M | NEW | 4.1M | 13.59 |
|
| Tyra Biosciences (TYRA) | 2.3 | $47M | +8% | 3.4M | 13.99 |
|
| Terns Pharmaceuticals (TERN) | 2.1 | $43M | NEW | 5.7M | 7.51 |
|
| Kymera Therapeutics (KYMR) | 2.1 | $43M | 750k | 56.60 |
|
|
| Mind Medicine Mindmed Com New (MNMD) | 1.9 | $38M | -35% | 3.2M | 11.79 |
|
| Nurix Therapeutics (NRIX) | 1.7 | $35M | -4% | 3.8M | 9.24 |
|
| Oruka Therapeutics (ORKA) | 1.6 | $34M | +23% | 1.8M | 19.23 |
|
| Spyre Therapeutics Com New (SYRE) | 1.6 | $33M | 2.0M | 16.76 |
|
|
| Bright Minds Biosciences Com New (DRUG) | 1.5 | $30M | 500k | 60.66 |
|
|
| Assembly Biosciences Com New (ASMB) | 1.2 | $26M | NEW | 1.0M | 25.60 |
|
| Cytomx Therapeutics (CTMX) | 1.2 | $25M | 7.7M | 3.19 |
|
|
| Lb Pharmaceuticals Com Shs | 1.2 | $24M | NEW | 1.5M | 15.79 |
|
| Tango Therapeutics (TNGX) | 0.6 | $13M | 1.5M | 8.40 |
|
|
| Apogee Therapeutics (APGE) | 0.6 | $12M | 290k | 39.73 |
|
|
| Pepgen (PEPG) | 0.5 | $11M | NEW | 2.4M | 4.62 |
|
| Enanta Pharmaceuticals (ENTA) | 0.5 | $9.6M | NEW | 800k | 11.97 |
|
| Sab Biotherapeutics Com New (SABS) | 0.4 | $8.8M | NEW | 4.4M | 2.01 |
|
| Inhibikase Therapeutics Com New (IKT) | 0.4 | $8.7M | 5.4M | 1.62 |
|
|
| Perceptive Cap Solutions Cor Cl A Ord Shs (PCSC) | 0.4 | $7.9M | 750k | 10.56 |
|
|
| Avalo Therapeutics Com New (AVTX) | 0.3 | $6.1M | 483k | 12.71 |
|
|
| Vistagen Therapeutics Ord (VTGN) | 0.3 | $5.6M | 1.6M | 3.55 |
|
|
| Crescent Biopharma (CBIO) | 0.3 | $5.4M | 451k | 11.89 |
|
Past Filings by Commodore Capital
SEC 13F filings are viewable for Commodore Capital going back to 2020
- Commodore Capital 2025 Q3 filed Nov. 14, 2025
- Commodore Capital 2025 Q2 filed Aug. 14, 2025
- Commodore Capital 2025 Q1 filed May 15, 2025
- Commodore Capital 2024 Q4 filed Feb. 14, 2025
- Commodore Capital 2024 Q3 filed Nov. 14, 2024
- Commodore Capital 2024 Q2 filed Aug. 14, 2024
- Commodore Capital 2024 Q1 filed May 15, 2024
- Commodore Capital 2023 Q4 filed Feb. 14, 2024
- Commodore Capital 2023 Q4 restated filed Feb. 14, 2024
- Commodore Capital 2023 Q3 filed Nov. 14, 2023
- Commodore Capital 2023 Q2 filed Aug. 14, 2023
- Commodore Capital 2023 Q1 filed May 15, 2023
- Commodore Capital 2022 Q4 filed Feb. 14, 2023
- Commodore Capital 2022 Q3 filed Nov. 14, 2022
- Commodore Capital 2022 Q2 filed Aug. 15, 2022
- Commodore Capital 2022 Q1 filed May 16, 2022